Avadel Pharmaceuticals (NASDAQ: AVDL) has announced the approval of inducement awards for nine new employees by its Board's Compensation Committee. The awards consist of non-statutory options to purchase 51,700 ordinary shares under the company's 2021 Inducement Plan. These options come with a ten-year term and follow a four-year vesting schedule: 25% vests after one year of employment, with the remaining portions vesting equally on the second, third, and fourth anniversaries. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.
Avadel Pharmaceuticals (NASDAQ: AVDL) ha annunciato l'approvazione di premi di incentivo per nove nuovi dipendenti da parte del Comitato per la Remunerazione del Consiglio di Amministrazione. I premi consistono in opzioni non statutarie per l'acquisto di 51.700 azioni ordinarie nell'ambito del Piano di Incentivazione 2021 della società. Queste opzioni hanno una durata di dieci anni e seguono un piano di maturazione quadriennale: il 25% matura dopo un anno di impiego, mentre le restanti quote maturano in modo uguale al secondo, terzo e quarto anniversario. Le concessioni sono state effettuate in conformità alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per l'accettazione dell'impiego.
Avadel Pharmaceuticals (NASDAQ: AVDL) ha anunciado la aprobación de premios de inducción para nueve nuevos empleados por parte del Comité de Compensación de su Junta Directiva. Los premios consisten en opciones no estatutarias para comprar 51,700 acciones ordinarias bajo el Plan de Inducción 2021 de la empresa. Estas opciones tienen un plazo de diez años y siguen un calendario de adquisición de derechos de cuatro años: el 25% se adquiere después de un año de empleo, y las porciones restantes se adquieren en partes iguales en el segundo, tercer y cuarto aniversario. Las concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como material de inducción para la aceptación del empleo.
Avadel Pharmaceuticals (NASDAQ: AVDL)는 이사회 보상위원회가 9명의 신입 사원에 대한 유인 보상 승인 소식을 발표했습니다. 이 보상은 회사의 2021년 유인 계획에 따라 51,700주의 보통주를 구매할 수 있는 비법정 옵션으로 구성됩니다. 이 옵션은 10년 기간이며 4년간의 권리 확득 일정에 따라 진행됩니다: 근무 1년 후 25%가 확득되며, 나머지는 2, 3, 4주년마다 동일하게 확득됩니다. 이 부여는 고용 수락을 위한 유인 자료로서 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Avadel Pharmaceuticals (NASDAQ : AVDL) a annoncé l'approbation des primes d'incitation pour neuf nouveaux employés par le comité de rémunération de son conseil d'administration. Les primes consistent en des options non statutaires d'achat de 51 700 actions ordinaires dans le cadre du plan d'incitation 2021 de la société. Ces options ont une durée de dix ans et suivent un calendrier d'acquisition de droits sur quatre ans : 25 % deviennent acquis après un an d'emploi, les parts restantes étant acquises également lors des deuxième, troisième et quatrième anniversaires. Les attributions ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'acceptation de l'emploi.
Avadel Pharmaceuticals (NASDAQ: AVDL) hat die Genehmigung von Anreizprämien für neun neue Mitarbeiter durch den Vergütungsausschuss des Vorstands bekanntgegeben. Die Prämien bestehen aus nichtstatutarischen Optionen zum Kauf von 51.700 Stammaktien im Rahmen des Inducement-Plans 2021 des Unternehmens. Diese Optionen haben eine zehnjährige Laufzeit und folgen einem vierjährigen Vesting-Zeitplan: 25 % werden nach einem Jahr Beschäftigung fällig, die restlichen Anteile jeweils gleichmäßig am zweiten, dritten und vierten Jahrestag. Die Zuteilungen erfolgten gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Annahme der Beschäftigung.
Positive
None.
Negative
None.
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
What is the vesting schedule for AVDL's new employee stock options granted in May 2025?
The options vest over 4 years, with 25% vesting on the first anniversary of each employee's start date and 25% vesting on the second, third, and fourth anniversaries.
How many ordinary shares were granted in Avadel's May 2025 inducement awards?
Avadel granted options to purchase 51,700 ordinary shares to nine new employees.
What is the term length of the AVDL stock options granted in May 2025?
The options have a ten-year term.
Under which plan were Avadel's May 2025 inducement awards granted?
The awards were granted under Avadel's 2021 Inducement Plan, approved by the Board of Directors in November 2021.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
